Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

® in combination with Halozyme's ENHANZE™ Technology

Upcoming Anticipated Milestones

  • Reintroduce Hylenex® recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and Ambulatory Surgery Centers - 4Q 2011
  • Discuss top line results from a Phase 1/2 study with HTI-501 in women with moderate to severe cellulite - 1H 2012
  • Present HannaH Phase 3 clinical trial data - 2012
  • Regulatory Submission Herceptin SC - 2012
  • Regulatory Submission Mabthera SC - 2012
  • PDUFA for Subcutaneous IgG Baxter Biosciences BLA - 2Q 2012
  • Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012

  • Third Quarter 2011 and Year-to-Date 2011 Financial ResultsThe net income for the third quarter of 2011 was $5.2 million, or $0.05 per share, compared with a net loss for the third quarter of 2010 of $(12.4) million, or $(0.13) per share. The net loss for the nine months ended September 30, 2011 was $(1.4) million, or $(0.01) per share, compared to a net loss of $(36.3) million, or $(0.39) per share, for comparable period in 2010.

  • Revenues for the third quarter of 2011 were $22.9 million, compared to $3.4 million for the third quarter of 2010. In July 2011, the Company and Baxter entered into agreements outlining certain rights, data and assets to be transferred to the Company in connection with the termination of the partnership with Baxter for the marketing rights of Hylenex recombinant. As a result, the Company recognized as revenue a one-time amount of $17.9 million from deferred revenues. Revenues in the third quarter of 2011 also consisted of a $3 million milestone payment from ViroPharma, the amortization of upfront payments received from Baxter and Roche of $0.6 million and research and development reimbursements from Baxter and Roche of $1.3 million.
  • Research and development expenses for the third quarter of 2011 were $13.5
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... Oct. 30, 2014  Ardelyx, Inc. (NASDAQ: ... on cardio-renal, gastrointestinal and metabolic diseases, today announced ... results on Thursday, November 6, 2014. Following the ... live conference call and webcast at 4:30pm ET ... a business update. The live webcast ...
    (Date:10/30/2014)... Texas (PRWEB) October 30, 2014 ... Naltrexone HCL Industry” is a professional and in-depth ... report provides basic Naltrexone HCL information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
    (Date:10/30/2014)... October 30, 2014 SoundConnect ... provider, offers Office 365 end users the key ... complete phone system by adding voice enablement and ... includes Lync Online, a communication tool that includes ... With hosted voice, O365 becomes a comprehensive unified ...
    (Date:10/30/2014)... MA (PRWEB) October 30, 2014 James Sherley ... advance in adult tissue stem cell technology since his days ... (FCCC) in Philadelphia in the late 1990’s. Sherley founded ... The company holds all the intellectual property developed in ... professor at the Massachusetts Institute of Technology (MIT), and more ...
    Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4
    ... Varian, Inc.,(NasdaqGS: VARI) today announced a plan to ... to close certain facilities. , ... economic environment,we are taking proactive steps to reduce our ... while continuing to invest in new product,development and maintaining ...
    ... Associates, Inc.,(SullivanCotter) has published its 16th 2008 Physician ... Notable findings this year,include an average salary increase ... physicians. Nearly three-quarters (72%) of the survey,participants ... 2008,which is comparable to last year, when 73% ...
    ... have entered into a research collaboration to improve insect control in ... ... Research Triangle Park, NC (Vocus) January 15, 2009 -– DuPont and ... improve insect control in corn and soybeans. Under the agreement, ...
    Cached Biology Technology:Varian, Inc. Announces Cost Reduction Plan 2Despite Economic Woes, Physician Compensation Increases 2Despite Economic Woes, Physician Compensation Increases 3DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 2DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 3
    (Date:10/28/2014)... awards to expand the Office of Rare Diseases ... Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical Research ... at 22 consortia will work with 98 patient ... new treatments for patients with rare diseases. The ... fiscal 2014 funding from NIH. , Rett syndrome, ...
    (Date:10/28/2014)... will be building a hybrid micro-grid which will ... first in the region, the hybrid micro-grid will ... tidal-current, diesel, storage and power-to-gas technologies, and ensure ... be built under the new Renewable Energy Integration ... be located offshore at Semakau Landfill and is ...
    (Date:10/27/2014)... are an indigenous species of the West Antarctic Peninsula ... Earth. Since 1950, the average annual temperature in the ... and 6 degrees Celsius during winter. , As ... dry, polar system to a warmer, sub-polar system with ... a connection between local weather conditions and the weight ...
    Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3University of Delaware study connects penguin chick weights to local weather conditions 2University of Delaware study connects penguin chick weights to local weather conditions 3
    ... Human Genome Research Institute (NHGRI), one of the National ... Sequencing Research Network will target 13 more organisms as ... that will expand biological knowledge and improve human health. ... (NACHGR), which is a federally chartered committee that advises ...
    ... proteins have evolved, UT Southwestern Medical Center researchers have ... to use to design proteins, rules the scientists have ... function just like their natural counterparts. , In two ... journal Nature, Dr. Rama Ranganathan, associate professor of pharmacology, ...
    ... swat a fly? The fly's secret in avoiding death in ... to fly out of the way. "This kind of low-power ... robots", according to Gwyneth Card of the California Institute of ... response at the Society for Experimental Biology Annual Main Meeting ...
    Cached Biology News:NHGRI Selects 13 More Organisms for Genome Sequencing 2NHGRI Selects 13 More Organisms for Genome Sequencing 3NHGRI Selects 13 More Organisms for Genome Sequencing 4NHGRI Selects 13 More Organisms for Genome Sequencing 5Researchers create functioning artificial proteins using nature's rules 2Researchers create functioning artificial proteins using nature's rules 3
    Mouse Wnt-9b Affinity Purified Polyclonal Ab Keywords: Wnt 9b Protein Family: Cancer Stem Cell Markers, Wnt Ligands...
    One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
    assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
    ...
    Biology Products: